A11 Venture
A11 Venture, founded in 2014 and based in Lucca, Italy, specializes in investing in innovative startups within the robotics, automation, mechatronics, cleantech, web, and information technology sectors. The company aims to foster the creation and growth of global businesses that contribute to the future of the local economy. A11 Venture plays a crucial role in building companies, generating qualified jobs, and promoting innovation through the development of patents. The firm is committed to facilitating investments and resources that can revitalize local areas. A11 Venture emphasizes the importance of innovation and strategic diversification in its investment portfolio, and it employs a professional approach to managing all processes involved, including scouting, team building, investment management, acceleration, and divestment.
Reefilla provides a mobile and predictive charging delivery service for electric vehicles. Reefilla enables people to charge their electric vehicles wherever and whenever they want, without disrupting their daily routine. Reefilla uses 100% green energy, fully electric vans for delivery, and gets its energy from used (second-life) batteries, contributing to net-zero emission by using a circular approach.
Neuron Guard, recognized as the best European startup in HEALTH category (Startup Europe Awards - SEUA 2017), is developing a life-saving medical device that aims to become the standard of care for Targeted Temperature Management (TTM) therapy. Every 7 seconds around the world a person suffers of Acute Brain Damage because of Cardiovascular Diseases (CVD) and Traumatic Brain Injury (TBI). They are the most costly and prevalent killers in the last 15 years (15 million deaths by CVD in 2015), and the leading cause of disability (the global incidence rate of TBI is 200 per 100k people per year). WHO estimated a global expenditure of $ 330 billion in 2015, but it is going to increase sharply: $ 4 trillion in 2025 - including premature death, disability, and health care costs - just for CVD in LMICs. Temperature is a vital body parameter. It regulates all cellular functions so its management is essential for the good outcome of patients in several medical conditions such as cardiac arrest, stroke, traumatic brain injury, neuro and cardiac surgery, epilepsy, migraine and oncology. Regulating body temperature at a desired level makes all other treatments more effective. The most modern medical approach is the target temperature management, where physicians try to maintain the most favourable temperature for the patient for up to 24-36 hours, preventing excessive warming (fever) or cooling. Our device is a targeted temperature management system composed by a THERAPEUTIC COLLAR POWERED BY A SMART CONTROL UNIT (the size of a small briefcase). The collar transforms the neck into a natural heat exchanger exploiting several physiological and anatomical characteristics of the human body. It is quicker to act on brain tissue but can also function as total body temperature adjusting device if required. A disposable protective shield makes cleaning the collar after each use simple while featuring an optimal safety profile both in term of pathogens and allergens. The control unit collects all the data of the treatment and transmits them to the Emergency Response System. Our mission is to improve the safety of patients on the roadside, at home or in the workplace, and to reduce the costs of chronic care. In fact, Neuron Guard aims to be the only device that can be used in every circumstance, inside and outside the hospital, and allow the user to fully manage the temperature of the patient warming and cooling as necessary. Our vision is to have a Neuron Guard kit in every public place just like the Automatic External Defibrillator (AED) to empower bystanders to immediately react in case of emergency. Under this perspective our device becomes a connected-intelligent platform that takes care of the patient, connects the scene with the Emergency Response System transmitting vital data to improve the readiness and effectiveness of professional intervention. The device is patented in Italy, USA and China. We have made several prototypes in collaboration with Italian and English companies, such as Tecno Elettra Impianti and TWI, tested it in laboratory and published the experimental results on the NeuroCritical Care Journal. We have also conducted a GAP Analysis with another English consulting firm (CDP) and we are testing the human prototype internally. We are seeking to raise 2.5M€ to complete the pre-industrialization, with design and construction of the human device for the pilot trial, finalized the regulatory clearance and launch it into the market in 2019.
INTA develops and manufactures portable laboratories on chip for rapid fluid analysis. The main applications are biomedical, safety, industry 4.0, and food analysis. They patented lab on a chip devices to detect a variety of analytes. INTA is developing its first product for the diagnosis of traumatic brain injuries with a rapid and portable system for blood analysis.
At 3dnextech, we are shaping the future of plastic part manufacturing and supply chain logic. Our technology transforms the material, making it pliable and malleable. By isolating the material at this stage, one can store it for later use to manufacture objects at room temperature. This process minimizes energy consumption and facilitates the reuse and recycling of waste materials throughout the entire supply chain. Produce less, produce better This revolutionary new approach to plastic production will transform the supply chain. It combines the ability to produce retail parts on-site, as enabled by additive manufacturing, with a finally competitive production capacity. This innovation will reduce the environmental costs associated with logistics and material transportation.
Spiiky is a creator of internet shopping planning that requires offering deals without requiring advance payment. Users can shop and receive appealing discounts whenever they want thanks to their company's application, which includes verified deals from local businesses or shopping cards from different international companies with discounts and rebates.
Mindesk is a Real-Time 3D design platform that integrates with existing commercial CAD software to extend its operations to Virtual Reality and Augmented Reality. Mindesk introduces the possibility to design a CAD project from scratch in Virtual Reality. Mindesk platform integrates directly with current CAD solutions and saves precious design steps: while the majority of VR CAD software commercially available require document exportation, Mindesk enables users to switch from VR to desktop seamlessly while editing the project in real-time on either platform.
Endostart develops and manufactures a new generation of medical devices for gastrointestinal endoscopy. It creates Magnetic Balloon Technology, which improves endoscope performance and allows endoscopists to easily meet quality standards. It was founded in collaboration with CNR, public research institutions, and high-tech suppliers.
Mindesk is a Real-Time 3D design platform that integrates with existing commercial CAD software to extend its operations to Virtual Reality and Augmented Reality. Mindesk introduces the possibility to design a CAD project from scratch in Virtual Reality. Mindesk platform integrates directly with current CAD solutions and saves precious design steps: while the majority of VR CAD software commercially available require document exportation, Mindesk enables users to switch from VR to desktop seamlessly while editing the project in real-time on either platform.
Adabra increase sales in your online store and in point of sales for marketer and retailers! Adabra is a web platform that allows you to increase the sales, offering the visitors a customized and enjoyable shopping experience. Increase the sales of your e-commerce. Give your customers a customized shopping experience by analyzing their behavior and showing them the most relevant products.
A pioneer of the circular economy, greenchic is the number 1 fashion-logistics startup in Southern Europe. Send us what you wish to swap, and immediately start buying with our reward points system. Thanks to this effortless service model, greenchic offers the fastest DTC way to regain value from no longer used clothing. Through greenchic, members can exchange items and revamp their style in an affordable, convenient and sustainable way. With 99% of the products sold, reused, upcycled, or donated to charities within 6 months, greenchic is set to become a European leader in circular fashion. With its growing user base, the highest customer retention rate in fashion recommerce, a 4.5-star TrustPilot rating, the platform offers to its highly engaged community a collection of more than 240.000 items. Thanks to a semi-automated logistic warehouse, an event-driven serverless digital platform, and its own digital token, the startup is experiencing a 2X growth pattern and is supported by some of the best investors from the Italian fashion & social impact scene. greenchic is now operating in Italy and France. Find out more by visiting greenchic.com and following @greenchic on socials.
Neuron Guard, recognized as the best European startup in HEALTH category (Startup Europe Awards - SEUA 2017), is developing a life-saving medical device that aims to become the standard of care for Targeted Temperature Management (TTM) therapy. Every 7 seconds around the world a person suffers of Acute Brain Damage because of Cardiovascular Diseases (CVD) and Traumatic Brain Injury (TBI). They are the most costly and prevalent killers in the last 15 years (15 million deaths by CVD in 2015), and the leading cause of disability (the global incidence rate of TBI is 200 per 100k people per year). WHO estimated a global expenditure of $ 330 billion in 2015, but it is going to increase sharply: $ 4 trillion in 2025 - including premature death, disability, and health care costs - just for CVD in LMICs. Temperature is a vital body parameter. It regulates all cellular functions so its management is essential for the good outcome of patients in several medical conditions such as cardiac arrest, stroke, traumatic brain injury, neuro and cardiac surgery, epilepsy, migraine and oncology. Regulating body temperature at a desired level makes all other treatments more effective. The most modern medical approach is the target temperature management, where physicians try to maintain the most favourable temperature for the patient for up to 24-36 hours, preventing excessive warming (fever) or cooling. Our device is a targeted temperature management system composed by a THERAPEUTIC COLLAR POWERED BY A SMART CONTROL UNIT (the size of a small briefcase). The collar transforms the neck into a natural heat exchanger exploiting several physiological and anatomical characteristics of the human body. It is quicker to act on brain tissue but can also function as total body temperature adjusting device if required. A disposable protective shield makes cleaning the collar after each use simple while featuring an optimal safety profile both in term of pathogens and allergens. The control unit collects all the data of the treatment and transmits them to the Emergency Response System. Our mission is to improve the safety of patients on the roadside, at home or in the workplace, and to reduce the costs of chronic care. In fact, Neuron Guard aims to be the only device that can be used in every circumstance, inside and outside the hospital, and allow the user to fully manage the temperature of the patient warming and cooling as necessary. Our vision is to have a Neuron Guard kit in every public place just like the Automatic External Defibrillator (AED) to empower bystanders to immediately react in case of emergency. Under this perspective our device becomes a connected-intelligent platform that takes care of the patient, connects the scene with the Emergency Response System transmitting vital data to improve the readiness and effectiveness of professional intervention. The device is patented in Italy, USA and China. We have made several prototypes in collaboration with Italian and English companies, such as Tecno Elettra Impianti and TWI, tested it in laboratory and published the experimental results on the NeuroCritical Care Journal. We have also conducted a GAP Analysis with another English consulting firm (CDP) and we are testing the human prototype internally. We are seeking to raise 2.5M€ to complete the pre-industrialization, with design and construction of the human device for the pilot trial, finalized the regulatory clearance and launch it into the market in 2019.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.